Hyperuricemia, characterized by elevated levels of serum uric acid (SUA), is linked to a
spectrum of commodities such as gout, cardiovascular diseases, renal disorders, metabolic …

The conventional paradigm of nonalcoholic fatty liver disease representing the “hepatic
manifestation of the metabolic syndrome” is outdated. We identified and summarized …

Xanthine oxidoreductase (XOR) could contribute to the pathogenesis of metabolic syndrome
through the oxidative stress and the inflammatory response induced by XOR-derived …

Background Allopurinol is the primary therapy for the management of chronic gout.
Utilization of allopurinol has increased in tandem with the growing prevalence of gout …

Obesity and related pathologies such as diabetes and metabolic syndrome are associated
with chronic inflammation and cancer. The serum level of xanthine oxidoreductase (XOR) is …

Emerging evidence has shown that serum uric acid (SUA) elevation might cause metabolic
derangements, including metabolic syndrome (MetS) and non-alcoholic fatty liver disease …

Background Some observational studies have suggested that serum uric acid (SUA) levels
are one of the determinants of the metabolic syndrome (MetS). However, previous studies …

Abstract Objective The metabolic syndrome (MetS) is a cluster of clinical indices that signals
increased risk for cardiovascular disease and Type 2 diabetes. The diagnosis of MetS is …

Background and aims Serum uric acid (SUA) has been recognized as an independent risk
factor for mortality in the general population. We performed this meta-analysis to determine …

This systematic review and meta-analysis aim to provide the best evidence on the
association between metabolic syndrome (MetS) and uric acid (UA) by determining the size …